After political leaders across the globe made patents and other intellectual property safeguards the scapegoat for disparities in access to COVID-19 vaccines, the biopharma industry is sharing its vision for how to deal with the foundational issues of equitable access in pandemics to come – and it has nothing to do with IP waivers like the one World Trade Organization members adopted last month.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acadia, Apellis, Astrazeneca, Avadel, Daiichi, Destiny, Gilead, Incyte, Moderna, Viking.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Antengene, Astrazeneca, Bavarian Nordic, BMS, Brii, Celularity, Creative, Inovio, Novavax, Oryzon, TSB, Turning Point.
Although it’s a latecomer to the COVID-19 pandemic in the U.S., there is a wedge of opportunity for Novavax Inc.’s adjuvanted protein-based vaccine among the 10% of the U.S. adult population that has yet to get a first jab.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cstone, Escend, Gilead, Moderna, Neurophth, Neximmune, Novartis, Omega, Polpharma, Prescient.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Codexis, Endo, GBT, Kalivir, N4, Nanomerics, Noxxon, Oncternal, Pfizer, Quoin, Scholar Rock, Serb, Siga, Soligenix, Voltron.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amryt, Beigene, G1, Lantern, Novavax, Revolo, Sinovac, Summit.
RSS
